The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The combination is also approved for a similar indication in the EU.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use on Monday recommended approval of AstraZeneca's tyrosine kinase inhibitor Tagrisso (osimertinib) as a ...

"I just needed something to mask the pain," she explained. The doctor ordered a scan to be on the safe side, and noticed ...

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.

Patients harboring EGFR mutations initially respond well to EGFR–TKIs, but acquired mutations render the patients resistant to the available drugs. These mutations include EGFR T790M point mutation.

Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of ...